Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Disease Natural History Grants Latest FDA Incentive For Drug Development

Executive Summary

Agency will make $2m available in 2017.

You may also be interested in...



Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies

NIH plans to select two dozen groups to participate in a Global Rare Disease Patient Registry pilot project, which FDA hopes will lead to a better understanding of the conditions and speed drug development.

Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says

CDER Director Janet Woodcock says rare disease advocates should consider organizing patients to study a rare disease history and progression.

ANDA Submissions Drop To Start FY2021

First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel